Aptinyx to Present at the SVB Securities Global Biopharma Conference
31 Janvier 2023 - 1:47PM
Business Wire
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced that Andy Kidd,
M.D., president & chief executive officer, will participate in
a virtual fireside chat at the SVB Securities Global Biopharma
Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.
A live webcast of the fireside chat will be available to view on
the “Events and Presentations” page in the “Investors & Media”
section of Aptinyx’s website at https://ir.aptinyx.com and will be
archived on Aptinyx’s website for 30 days following the event.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders. Aptinyx has a platform for discovery
of novel compounds that work through a unique mechanism to
modulate—rather than block or over-activate—NMDA receptors and
enhance synaptic plasticity, the foundation of neural cell
communication. The company has three product candidates in clinical
development in central nervous system indications, including
cognitive impairment, post-traumatic stress disorder, and opioid
use disorder. Aptinyx is also advancing additional compounds from
its proprietary discovery platform, which continues to generate a
rich and diverse pipeline of small-molecule NMDA receptor
modulators with the potential to treat an array of neurologic
disorders. For more information, visit www.aptinyx.com.
Source: Aptinyx Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230131005510/en/
Investor and Media Contact: Patrick Flavin Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com 847-871-0377
Aptinyx (NASDAQ:APTX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Aptinyx (NASDAQ:APTX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024